Triple negative breast cancer, which is characterized by the lack of expression of the estrogen and progesterone receptors and by amplification of human epidermal growth factor receptor 2 (HER2)/Neu, offers a particularly poor prognosis with limited therapeutic options and thus urgently requires new treatment approaches [2]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.